SYS-CON MEDIA Authors: Elizabeth White, Plutora Blog, Jayaram Krishnaswamy, Liz McMillan, Javier Paniza

News Feed Item

Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, March 18, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Cell  Therapeutics,  Inc.  Analyst  Notes

On March 3, 2014, Cell Therapeutics, Inc. (CTI) announced the initiation of a Phase 3 clinical trial, PERSIST-2, evaluating pacritinib. Pacritinib is a novel investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL). "With the initiation of the PERSIST-2 trial, we believe that the registration program for pacritinib is on track for a potential NDA submission in the latter part of 2015," said James A. Bianco, MD, President and CEO of CTI. "We have seen meaningful clinical benefits and good tolerability with pacritinib in myelofibrosis patients in Phase 2 trials without apparent drug-related thrombocytopenia or anemia. As such, we have had strong interest in site participation for this trial and will work diligently to activate these sites over the next several months." The trial is expected to enroll up to 300 patients in North America, Europe, Australia and New Zealand within 12 to 14 months. The full analyst notes on Cell Therapeutics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/CTIC/report.pdf

Intrexon  Corporation  Analyst  Notes

On March 7, 2014, Intrexon Corp. (Intrexon) announced that it has completed the acquisition of Medistem, Inc., a pioneer in the development of Endometrial Regenerative Cells. Under the terms of the agreement, Medistem stockholders will receive in exchange for each share of Medistem common stock $0.27 in cash and $1.08 worth of Intrexon common stock, or approximately 0.03920 shares. This is based on the 20-day volume-weighted average price of Intrexon's common stock immediately prior to closing, subject to adjustment pursuant to the terms of the merger agreement. The full analyst notes on Intrexon Corporation are available to download free of charge at:

http://www.AnalystsReview.com/03182014/XON/report.pdf

Chimerix,  Inc.  Analyst  Notes

On March 7, 2014, Chimerix Inc. (Chimerix) reported its Q4 2013 and full-year 2013 financial results. For the quarter, the Company reported a net loss of $8.2 million or $0.31 per basic and diluted share,compared to a net loss of $4.3 million or $3.90 per basic and diluted share in Q4 2012. Revenues totaled $879,000, compared to $3.6 million in Q4 2012. For full-year 2013, net loss was $36.4 million or $3.65 per basic and diluted share, compared to net loss of $4.4 million or $5.75 per basic and diluted share in 2012. Revenues were $4.4 million, compared to $33.7 million in 2012. The decrease in revenues were attributable to a decrease in reimbursable expenses associated with Chimerix's ongoing contract with BARDA in 2013, and the receipt of an upfront license payment related to Chimerix's collaboration and license arrangement with Merck in 2012. The full analyst notes on Chimerix, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/CMRX/report.pdf

Receptos,  Inc.  Analyst  Notes

On March 5, 2014, Receptos, Inc. (Receptos) reported its Q4 2013 and full-year 2013 (period ended December 31, 2013) financial results. For the quarter, the Company reported net loss of $15.2 million, or $0.86 per common share, compared to a net loss of $4.5 million, or $3.08 per common share, in Q4 2012. Total revenues were $773,000, compared to $3.8 million in Q4 2012. Revenue during these periods consisted primarily of amortization of up-front fees and milestone payments, and development funding received from our collaborative arrangements. Fiscal year 2013 net loss was as $50.4 million, or $4.23 per common share, compared to a net loss of $17.7 million, or $13.73 per common share, in 2012. Total revenues were $4.6 million compared to $8.6 million in 2012. The full analyst notes on Receptos, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/RCPT/report.pdf

Revance  Therapeutics,  Inc.  Analyst  Notes

On March 12, 2014, Revance Therapeutics, Inc. (Revance) announced the schedule of its earnings release and conference call. The Company will report its Q4 2013 and full-year 2013 financial results on March 26, 2014, Wednesday, after the close of market. The Company's management will also host a conference call and live internet webcast on the same day at 1:30 p.m. PT or 4:30 p.m. ET to discuss the results as well as provide business updates. The webcast will be available in the Investor Relations section on the Company's website for 30 days following the completion of the call. The full analyst notes on Revance Therapeutics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/RVNC/report.pdf

About Analysts Review

We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR  NOTES:

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For  any  urgent  concerns  or  inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE  PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT  FINANCIAL  ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO  WARRANTY  OR  LIABILITY  ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The Internet of Things (IoT) promises to evolve the way the world does business; however, understanding how to apply it to your company can be a mystery. Most people struggle with understanding the potential business uses or tend to get caught up in the technology, resulting in solutions that fail to meet even minimum business goals. In his session at @ThingsExpo, Jesse Shiah, CEO / President / Co-Founder of AgilePoint Inc., showed what is needed to leverage the IoT to transform your business. ...
IoT is still a vague buzzword for many people. In his session at @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, discussed the business value of IoT that goes far beyond the general public's perception that IoT is all about wearables and home consumer services. He also discussed how IoT is perceived by investors and how venture capitalist access this space. Other topics discussed were barriers to success, what is new, what is old, and what th...
Dale Kim is the Director of Industry Solutions at MapR. His background includes a variety of technical and management roles at information technology companies. While his experience includes work with relational databases, much of his career pertains to non-relational data in the areas of search, content management, and NoSQL, and includes senior roles in technical marketing, sales engineering, and support engineering. Dale holds an MBA from Santa Clara University, and a BA in Computer Science f...
The Internet of Things (IoT) is rapidly in the process of breaking from its heretofore relatively obscure enterprise applications (such as plant floor control and supply chain management) and going mainstream into the consumer space. More and more creative folks are interconnecting everyday products such as household items, mobile devices, appliances and cars, and unleashing new and imaginative scenarios. We are seeing a lot of excitement around applications in home automation, personal fitness,...
“The year of the cloud – we have no idea when it's really happening but we think it's happening now. For those technology providers like Zentera that are helping enterprises move to the cloud - it's been fun to watch," noted Mike Loftus, VP Product Management and Marketing at Zentera Systems, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The Industrial Internet revolution is now underway, enabled by connected machines and billions of devices that communicate and collaborate. The massive amounts of Big Data requiring real-time analysis is flooding legacy IT systems and giving way to cloud environments that can handle the unpredictable workloads. Yet many barriers remain until we can fully realize the opportunities and benefits from the convergence of machines and devices with Big Data and the cloud, including interoperability, ...
OneCloud Software has launched the OneCloud Partner Program. Responding to demand from prospective partners, the Program offers managed service providers (MSPs) and resellers the resources they need to grow their business with the OneCloud Recovery solution. OneCloud Recovery is an automated solution for disaster recovery/business continuity (DR/BC), which leverages Amazon Web Services as the disaster recovery site. “This is a tremendous opportunity with an innovative hybrid cloud-based DR pro...
"ElasticBox is an enterprise company that makes it very easy for developers and IT ops to collaborate to develop, build and deploy applications on any cloud - private, public or hybrid," stated Monish Sharma, VP of Customer Success at ElasticBox, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Cloud Technology Partners on Wednesday announced it has been recognized by the Modern Infrastructure Impact Awards as one of the Best Amazon Web Services (AWS) Consulting Partners. Selected by the editors of TechTarget's SearchDataCenter.com, and by votes from customers and strategic channel partners, the companies acknowledged by the Modern Infrastructure Impact Awards represent the top providers of cloud consulting services for AWS including application migration, application development, inf...
MapR Technologies on Tuesday announced the availability of free Hadoop On-Demand Training for developers, analysts and administrators which represents a $50M in-kind contribution* to the broad Hadoop community. The Hadoop training program is a multi-course curriculum designed to expand worldwide adoption of Hadoop technology. The curriculum provides engaging and interactive video lessons, hands-on exercises, labs and quizzes, enabling professionals to acquire valuable Hadoop skills and knowledge...
“We help people build clusters, in the classical sense of the cluster. We help people put a full stack on top of every single one of those machines. We do the full bare metal install," explained Greg Bruno, Vice President of Engineering and co-founder of StackIQ, in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
"Blue Box has been around for 10-11 years, and last year we launched Blue Box Cloud. We like the term 'Private Cloud as a Service' because we think that embodies what we are launching as a product - it's a managed hosted private cloud," explained Giles Frith, Vice President of Customer Operations at Blue Box, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
In this demo at 15th Cloud Expo, John Meza, Product Engineer at Esri, showed how Esri products hook into Hadoop cluster to allow you to do spatial analysis on the spatial data within your cluster, and he demonstrated rendering from a data center with ArcGIS Pro, a new product that has a brand new rendering engine.
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
"People are a lot more knowledgeable about APIs now. There are two types of people who work with APIs - IT people who want to use APIs for something internal and the product managers who want to do something outside APIs for people to connect to them," explained Roberto Medrano, Executive Vice President at SOA Software, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.